碳-11蛋氨酸PET代谢肿瘤体积反应评估可识别胶质母细胞瘤进展预测亚区
本研究基于I/II期剂量递增放化疗试验,评估新诊断胶质母细胞瘤患者3个月时碳-11蛋氨酸PET(MET-PET)反应评估与预后的关联。复发时GTV-Gd覆盖97%的持续MET-PET亚区,持续亚区是定位复发的最强预测因子。
要点
- 复发GTV-Gd覆盖97%的持续MET-PET亚区,持续亚区最能定位复发。
核心结论
- 多数影像学全切的胶质母细胞瘤患者术后仍存在可测量的MTV。
- 放化疗后3个月总MTV和持续MTV是PFS的显著预测因子,持续MET-PET亚区是定位肿瘤复发的最强预测因子。
研究设计与样本
- 研究为基于解剖MRI的剂量递增放化疗I/II期试验的事后分析,共纳入37例新诊断胶质母细胞瘤患者。
- MET-PET代谢肿瘤体积(MTV)采用小脑平均摄取1.5倍阈值自动分割,PFS和OS用Kaplan-Meier法估计并log-rank检验,多因素分析用Cox比例风险模型。
主要发现
- 37例中15例全切,其中10例(67%)有残留MTV;16例次全切,6例仅活检。
- 中位放疗剂量75 Gy(范围66-81),基线T1增强肿瘤体积(GTV-Gd)中位38.0 cm3(范围8.0-81.5),放化疗前MTV中位4.9 cm3(范围0-43.8)。
- 复发时GTV-Gd覆盖持续MET-PET亚区的97%(四分位距72%-100%),覆盖基线MTV的71%(39%-93%)、基线GTV-Gd的54%(18%-87%)和3个月MTV的78%(47%-95%)。
关键数值与推荐
- MET-PET MTV自动分割阈值定义为小脑平均摄取1.5倍。
临床怎么用
- 对新诊断胶质母细胞瘤患者,术后及放化疗后3个月可考虑MET-PET评估MTV,辅助识别残留代谢活性病灶。
- 3个月MTV=0提示PFS可能更优,MTV较大或持续存在提示PFS不良风险较高。
- 持续MET-PET亚区与复发部位高度重叠,可用于指导复发定位和局部加量策略的探索。
局限性
- 研究为单臂I/II期试验的事后分析,样本量37例,3个月MET-PET仅25例,统计效能有限。
- MTV自动分割阈值基于小脑平均摄取1.5倍,尚未在外部队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate whether response assessment of newly diagnosed glioblastoma at 3 months using 11C-methionine-positron emission tomography (MET-PET) is better associated with patient outcome compared with baseline MET-PET or anatomic magnetic resonance imaging alone. METHODS AND MATERIALS: Patients included were participants in a phase I/II trial of dose-escalated chemoradiation based on anatomic magnetic resonance imaging. Automated segmentation of metabolic tumor volume (MTV) was performed at a threshold of 1.5 times mean cerebellar uptake. Progression-free (PFS) and overall survival were estimated with the Kaplan-Meier method and compared with log-rank tests. Multivariate analysis for PFS and overall survival was performed using Cox proportional hazards, and spatial overlap between imaging and recurrence volumes were analyzed. RESULTS: Among 37 patients, 15 had gross total resection, of whom 10 (67%) had residual MTV, 16 subtotal resection, and 6 biopsy alone. Median radiation therapy dose was 75 Gy (range, 66-81). Median baseline T1 Gd-enhanced tumor volume (GTV-Gd) was 38.0 cm3 (range, 8.0-81.5). Median pre-CRT MTV was 4.9 cm3 (range, 0-43.8). Among 25 patients with 3-month MET-PET, MTV was only 2.4 cm3 (range, 0.004-18.0) in patients with uptake. Patients with MTV = 0 cm3 at 3 months had superior PFS (18.2 vs 10.1 months, P = .03). On multivariate analysis, larger 3-month MTV (hazard ratio [HR] 2.4, 95% confidence interval [CI], 1.4-4.3, P = .03), persistent MET-PET subvolume (overlap of pre-CRT and 3 month MTV; HR 2.0, 95% CI, 1.2-3.4, P = .06), and increase in MTV (HR 1.8, 95% CI, 1.1-3.1, P = .09) were the only imaging factors significant for worse PFS. GTV-Gd at recurrence encompassed 97% of the persistent MET-PET subvolume (interquartile range 72%-100%), versus 71% (interquartile range 39%-93%) of baseline MTV, 54% of baseline GTV-Gd (18%-87%), and 78% of 3-month MTV (47%-95%). CONCLUSIONS: The majority of patients with apparent gross total resection of glioblastoma have measurable postoperative MTV. Total and persisting MTV 3 months post-CRT were significant predictors of PFS, and persistent MET-PET subvolume was the strongest predictor for localizing tumor recurrence.
引用
- Miller S, Li P, Schipper M, et al. Metabolic Tumor Volume Response Assessment Using (11)C-Methionine Positron Emission Tomography Identifies Glioblastoma Tumor Subregions That Predict Progression Better Than Baseline or Anatomic Magnetic Resonance Imaging Alone. Adv Radiat Oncol. 2019. PMID: 32051890. doi:10.1016/j.adro.2019.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。